US 11,718,685 B2
Compositions and methods for targeting stromal cells for the treatment of cancer
Carl H. June, Merion Station, PA (US); Ellen Pure, Bryn Mawr, PA (US); Liang-Chuan Wang, Philadelphia, PA (US); Steven Albelda, Philadelphia, PA (US); and John Scholler, Penn Valley, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Filed on May 20, 2019, as Appl. No. 16/417,125.
Application 15/158,727 is a division of application No. 14/042,306, filed on Sep. 30, 2013, granted, now 9,365,641, issued on Jun. 14, 2016.
Application 16/417,125 is a continuation of application No. 15/158,727, filed on May 19, 2016, granted, now 10,329,355.
Claims priority of provisional application 61/708,336, filed on Oct. 1, 2012.
Prior Publication US 2020/0079874 A1, Mar. 12, 2020
Int. Cl. C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/18 (2013.01); C07K 16/30 (2013.01); C07K 2317/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01); C12N 2710/10343 (2013.01)] 8 Claims
 
1. A chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain derived from an F19 binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the antigen binding domain binds to a stromal cell antigen, and wherein the antigen binding domain comprises:
(a) a light chain variable region comprising a light chain complementary region 1 comprising the amino acids 24-39 of SEQ ID NO:9 (RSSQSIVHSNGNTYLE), a light chain complementary region 2 comprising the amino acids 55-61 of SEQ ID NO: 9 (KVSNRFS), a light chain complementary region 3 comprising amino acids 94-102 of SEQ ID NO: 9 (FGGSHVPYT); or
(b) a heavy chain variable region comprising a heavy chain complementary region 1 comprising the amino acids 30-34 of SEQ ID NO: 8 (SYGMS), a heavy chain complementary region 2 comprising the amino acids 49-65 of SEQ ID NO: 8 (TTNNNGGVTYYPDSVKG), a heavy chain complementary region 3 comprising the amino acids 98-105 (YGYYAMDY).